# A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

> **NCT06906900** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Spinal Metastasis

## Interventions

- **DEVICE:** TTF-200M and TTF-200A systems

## Key facts

- **NCT ID:** NCT06906900
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2027-02-17
- **Final completion:** 2029-02-17
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06906900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06906900, "A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06906900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*